Battery Ventures to Take Private Enzo Biochem in All-Cash Transaction

BioMarin Pharmaceutical Completes Acquisition of Inozyme Pharma

May 16, 2025

Healthcare Services

BioMarin Pharmaceutical Inc. completed its all-cash acquisition of Inozyme Pharma, Inc. for $4.00 per share, valuing the deal at approximately $270 million. The transaction adds INZ-701, a late-stage enzyme replacement therapy being developed for ENPP1 Deficiency, to BioMarin’s enzyme therapies portfolio.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.

Roche to Acquire 89bio for Up to $3.5 Billion

September 22, 2025

Pharmaceuticals

Roche has reached an agreement to acquire 89bio, a biopharmaceutical company focused on treatments for liver diseases and cardiometabolic conditions. The deal is expected to close in the fourth quarter of 2025, with an offered price of $14.50 per share in cash plus potential contingent value rights tied to performance milestones for pegozafermin.

Harmony Biosciences Acquires Zynerba Pharmaceuticals

August 14, 2023

Pharmaceuticals

Harmony Biosciences Holdings, Inc. has signed a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. in a cash tender offer valued at $60 million at closing ($1.1059 per share) plus a non-tradeable contingent value right (CVR) with potential additional payments of up to $140 million, for total potential consideration of up to $200 million. The deal is expected to close in the fourth quarter of 2023, subject to customary closing conditions and tendering by at least a majority of Zynerba’s outstanding shares.

Bain Capital Takes Envestnet Private in $4.5B Transaction

July 11, 2024

Financial Services

Envestnet, Inc. entered into a definitive agreement to be acquired by affiliates of vehicles managed or advised by Bain Capital, valuing the company at $4.5 billion ($63.15 per share). The deal received stockholder approval and closed in November 2024, taking Envestnet private and removing its common stock from public listing.

Eli Lilly and Company to Acquire Ventyx Biosciences

January 8, 2026

Pharmaceuticals

Eli Lilly and Company has entered into a definitive agreement to acquire Ventyx Biosciences for approximately $1.2 billion. The deal values Ventyx at $14.00 per share in cash and is expected to close in the first half of 2026, subject to shareholder and regulatory approvals.